Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSBR-1290 PK/PD in Japanese and Non-Japanese Healthy Volunteers
NCT05893043Phase 1Completed
- Sponsor
- Gasherbrum Bio
- Start
- Apr 2023
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of aleniglipron in type 2 diabetes mellitus (T2DM) and obesity (2 cohorts), sponsored by Gasherbrum Bio. Primary endpoints: Number of Participants With Adverse Events (AEs) and Serious AEs, Number of Participants Based on Severity of AEs and 3 more. Started Apr 2023; status: completed.
02
Drugs
aleniglipron
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT05893043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05893043.